T/w/In

Attorney Docket No. P1959R1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Application of

Dorothy French, et al.

Serial No.: 10/516,868

Filed: December 3, 2004

For: COMPOSITIONS AND METHODS

FOR THE DIAGNOSIS AND TREATMENT OF TUMOR

Group Art Unit: 1633

Examiner: Hiriyanna, Kelaginamanet

Confirmation No: 1564

CUSTOMER NO: 09157

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450,

Alexandria, VA 22313-1450 on 6 - 29 - 06

By: Dam Golden

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

[] 37 CFR §1.97(b)

- •within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
- •within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§1.491, or
- •before the mailing of the first Office action on the merits; or
- •before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

[X] 37 CFR §1.97(c)

by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

[] 37 CFR §1.97(d)

after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) and a statement as specified in 37 CFR §1.97(e), as checked below.

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

[] 37 CFR §1.97(e)

Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

[] 37 CFR §1.704(d)

Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.

[X] The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) and/or publication(s) is set forth on the attached revised Form PTO-1449.

A copy of the items listed on the PTO-1449 form are supplied herewith, except for those patent(s), publication(s) or other information which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied because a)[] they were previously cited by or submitted to the Office in a prior application Serial No., filed and relied upon in this application for an earlier filing date under 35 USC §120 and/or because b)[X] copies of United States patents and United States patent application publications are not required unless requested by the Office. 37 CFR §1.98(a)(2)(ii). See Final Rule 1287 OG (October 12, 2004). Applicants stand ready to provide copies at the request of the Examiner.

A concise explanation of relevance of the items listed on PTO-1449 is:

- [x] not given
- [] given for each listed item
- given for only non-English language listed item(s) [Required]

[] in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. <u>07-</u> <u>0630</u>. A duplicate copy of this sheet is enclosed.

Respectfully	submitted.
respectivity	submitted,

GENENTECH, INC.

Date: 6/29/06

Cara M. Coburn

Reg. No. 46,631

Telephone No. (650) 467-6222

Sheet	1	of	1

FORM PTO-1449 U.S. Dept. of Co		U.S. Dept. of Commerce	Atty Docket No.	Serial	No.			
101111111111111111111111111111111111111				P Patent and Trademark Office	P1959R1	10/516,868		
HET	UE DIO	SCLOSURES CITED B	V ADDI ICANT	O P E dion and Trademain onios	Applicant French Dorothy			
			. /	/ B	Filing Date	Group		
U)	se seve	eral sheets if necessar	"	101 0 3 5000 E	03 Dec 2004	1632	•	
			3	U.S. PATENT DOCUMENTS				
Examiner		D	•	MATE	Class	Subalasa	Filing Data	
nitials	*237	Document Number 2005/0026832	03.02.05	Name Adams, et al.	Class	Subclass	Filing Date	
	-237	2005/0026632	03.02.03	FOREIGN PATENT DOCUMENTS		1		
Examiner				TONLIGHT FATERT DOCUMENTS	,		Translation	
nitials		Document Number	Date	Country	Class	Subclass	Yes No	
	*238	WO 01/18210	15.03.01	PCT				
				OSURES (Including Author, Title, Date,				
<u></u>	239	of fibroblast gro	owth factor 19 : (Jun 2002)	mal Model: A mouse model of hepa in skeletal muscle of transgenic	mice" <u>American Jo</u>	urnal of	Pathology	
	240	Tomlinson, E., et Metabolic Rate ar	d Decreased Ad	nic Mice Expressing Human Fibrob iposity" <u>Endocrinology</u> 143(5):17	41-1747 (2002)	-19 Dispi	ay Increased	
					. 41 1 1 10 10 10 10 10 10 10 10 10 10 10 1			
								
					·	<u> </u>		
					<u> </u>			
•				· · · · · · · · · · · · · · · · · · ·				
						<u> </u>		
		<u>.</u>	· · · · · · · · · · · · · · · · · · ·					
							<u> </u>	
							•	
Examine	er	,	,		Pate Considered			
*Examin	ner: In	itial if reference consider	dered, whether or n	ot citation is in conformance with MPEP	609; draw line through	citation		